Bbva Compass Bancshares Inc. lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 6.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 12,286 shares of the medical instruments supplier’s stock after selling 803 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Becton, Dickinson and were worth $2,397,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Boston Financial Mangement LLC boosted its stake in shares of Becton, Dickinson and by 10.2% in the first quarter. Boston Financial Mangement LLC now owns 55,702 shares of the medical instruments supplier’s stock valued at $10,218,000 after buying an additional 5,152 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock valued at $602,246,000 after buying an additional 39,362 shares during the last quarter. AMG National Trust Bank boosted its stake in shares of Becton, Dickinson and by 4.2% in the first quarter. AMG National Trust Bank now owns 9,880 shares of the medical instruments supplier’s stock valued at $1,813,000 after buying an additional 401 shares during the last quarter. Nationwide Fund Advisors boosted its stake in shares of Becton, Dickinson and by 64.2% in the first quarter. Nationwide Fund Advisors now owns 96,582 shares of the medical instruments supplier’s stock valued at $17,717,000 after buying an additional 37,752 shares during the last quarter. Finally, Fundsmith LLP boosted its stake in shares of Becton, Dickinson and by 3.2% in the first quarter. Fundsmith LLP now owns 2,296,613 shares of the medical instruments supplier’s stock valued at $421,291,000 after buying an additional 71,691 shares during the last quarter. 87.41% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company (BDX) opened at 198.90 on Wednesday. The firm’s 50-day moving average is $200.05 and its 200 day moving average is $189.42. The stock has a market capitalization of $45.26 billion, a PE ratio of 57.60 and a beta of 1.05. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same quarter in the prior year, the business posted $2.35 EPS. The business’s revenue was down 5.1% compared to the same quarter last year. On average, equities analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.47%. Becton, Dickinson and’s payout ratio is 83.43%.

COPYRIGHT VIOLATION WARNING: “Becton, Dickinson and Company (BDX) Stake Reduced by Bbva Compass Bancshares Inc.” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/08/30/becton-dickinson-and-company-bdx-stake-reduced-by-bbva-compass-bancshares-inc.html.

Several research analysts have issued reports on BDX shares. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a research report on Monday, July 17th. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price target for the stock from $210.00 to $180.00 in a research report on Friday, June 30th. BidaskClub upgraded shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. Cowen and Company restated a “buy” rating and issued a $230.00 price target on shares of Becton, Dickinson and in a research report on Monday, August 14th. Finally, Bank of America Corporation restated a “buy” rating and issued a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $195.79.

In related news, insider Ellen R. Strahlman sold 9,283 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the transaction, the insider now owns 26,638 shares in the company, valued at $5,279,917.98. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Linda M. Tharby sold 4,695 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total transaction of $941,253.60. Following the transaction, the executive vice president now owns 18,670 shares of the company’s stock, valued at approximately $3,742,961.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,605 shares of company stock valued at $9,718,986. Company insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.